Generative AI is steadily moving from pilot projects into mission-critical operations—and not just in the private sector. This week, CloudMoyo announced that its IntelliDoc Analyze (CDA) platform is being deployed to modernize contract lifecycle management for AIDS Healthcare Foundation (AHF), the world’s largest nonprofit provider of HIV/AIDS care.
AI is quietly reshaping clinical trials—and not just by speeding up drug discovery. In a notable milestone for medical imaging and respiratory research, Brainomix has been selected by Boehringer Ingelheim to provide AI-powered imaging biomarkers as a co-primary endpoint in a Phase 3 pulmonary fibrosis study.
That’s the central tension revealed in Redwood Software’s “Manufacturing AI and Automation Outlook 2026,” a new global study based on a survey of 300 manufacturing professionals conducted by independent research firm Leger Opinion. The findings point to a widening automation gap: while AI ambitions are sky-high and investments in OT, ET, and IT automation are well underway, most manufacturers remain stuck in the middle of the maturity curve.
This week, the company unveiled DDC Evora™, a new agentic AI platform designed to handle complex customer interactions with human-like understanding while driving measurable operational gains. The launch positions DDC squarely in the growing market for AI systems that go beyond scripted workflows and rigid decision trees—systems that can interpret intent, adapt in real time, and collaborate with human agents rather than simply deflect calls.
The inaugural Global Business Connectivity Outlook Report 2025–26 paints a picture of confidence colliding with contradiction. More than 70% of surveyed business leaders plan to expand beyond their local region next year, yet the very infrastructure that makes regional and global operations viable—reliable, secure connectivity—is being deprioritized in favor of AI-heavy investments.
